PH12016500330B1
(en )
2016-05-02
Certain chemical entities, compositions, and methods
PH12019502810A1
(en )
2021-01-11
Bicyclic heterocycles as fgfr inhibitors
PH12017500509A1
(en )
2017-08-30
Benzyl substituted indazoles as bub1 inhibitors
CL2015001985A1
(en )
2015-10-02
Thiazolcarboxamides and pyridinecarboxamide compounds, pim kinase inhibitors.
MX2018008052A
(en )
2019-03-14
Lsd1 inhibitors.
MX2019001125A
(en )
2019-06-12
Macrocycle kinase inhibitors.
PH12016500739A1
(en )
2016-05-30
Inhibitors of the fibrolast growth factor receptor
MX371108B
(en )
2020-01-17
Pyrimidopyrimidinones useful as wee-1 kinase inhibitors.
MX2016003843A
(en )
2017-02-15
Irak inhibitors and uses thereof.
CL2015002932A1
(en )
2016-04-22
Protein kinase inhibitors
MY187540A
(en )
2021-09-28
Compounds active towards bromodomains
NZ724691A
(en )
2018-02-23
Quinoline derivatives as smo inhibitors
MX2015008999A
(en )
2015-09-16
Mk2 inhibitors and uses thereof.
IL253979A0
(en )
2017-10-31
Methods, compositions, and kits for treatment of cancer
PH12015502041B1
(en )
2016-01-18
Heteroaryl compounds and uses thereof
MX2015011899A
(en )
2016-05-05
Methods of treating cancer and preventing cancer drug resistance.
MX2015011606A
(en )
2016-05-17
Methods of treating cancer and preventing cancer drug resistance.
MX2015006478A
(en )
2015-12-03
Glutamase inhibitors and method of use.
MX2020001756A
(en )
2020-07-28
Benzoquinolone inhibitors of vmat2.
MX2016004570A
(en )
2016-09-08
Use of cbp/ep300 bromodomain inhibitors for cancer immunotherapy.
TN2015000411A1
(en )
2017-01-03
Ceftolozane antibiotic compositions
EP2670763A1
(en )
2013-12-11
Certain chemical entities, compositions, and methods
MX2016009655A
(en )
2016-11-09
Novel methods for treating cancer.
PH12016501838A1
(en )
2017-01-09
Compounds and their methods of use
MX2015013021A
(en )
2016-07-14
5-bromo-indirubins.